Three new factsheets on direct-acting antivirals used to
treat hepatitis C are available now on infohep.org. You can
read the factsheets online or download them as print-friendly PDFs.
New hepatitis C drugs
If you have an interest in hepatitis C treatment research, you will
have noticed a huge amount of activity in the last few years. There are new
drugs in development and that means lots of studies, looking at how effective
they are for different people, how safe they are, what side-effects people
experience and much more. All of these studies produce lots of important data
which should inform
the decisions people make about treatment.
It is an exciting time for hepatitis C treatment, as the
newer drugs coming to the market generally have fewer side-effects and are
easier to take than the previous standard treatments. However, the wealth of
detailed information on all these new drugs can be overwhelming. If you’re
someone living with hepatitis C, or someone who cares for people living with
hepatitis C, where do you start?
We are offering you an answer – start with our new
Hepatitis C treatment
We have produced three factsheets, on key new direct-acting
antiviral drugs. Each factsheet gives information such as how the drug works,
who can use it, how it is taken, how effective it is and the side-effects
reported by people taking it.
Each factsheet is available to read online, or to download
as a print-friendly PDF. Please print and share these factsheets with anyone
you think would find them helpful.
For more information
We launched these factsheets at the recent International Liver
Congress in London and the response was positive and enthusiastic! If you
have any feedback, please do let us know. You can email us at firstname.lastname@example.org.
Thank you to everyone involved in the development of these
resources. We would particularly like to thank Liz Highleyman (hivandhepatitis.com) for her work on
We are grateful to
Janssen for funding the development of these factsheets. Janssen has had no
editorial control over the content.